Transitional cell carcinoma

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This study tests whether adding the drug eribulin to standard chemotherapy can help people with advanced bladder cancer live longer. It is for patients whose cancer has spread and no longer responds to immunotherapy. About 184 participants will receive either the new combination …

Researchers at Dana-Farber Cancer Institute are testing whether information from a bladder tumor's genes, combined with how the tumor responds to chemotherapy, can help doctors and patients decide between bladder-sparing chemoradiation and surgery to remove the bladder. The study…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

Researchers are studying eribulin mesylate, a chemotherapy drug, in people with urothelial cancer that has spread or cannot be removed by surgery, and who also have kidney problems. The trial has two parts: one to find the highest dose patients can tolerate, and another to see ho…

This early-phase study tests two drugs, bintrafusp alfa and PDS01ADC, alone or with targeted radiation, in 100 adults with metastatic bladder, kidney, or other non-prostate genitourinary cancers. The goal is to see if the combination can help the immune system fight cancer better…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…

This phase 2 trial tests whether adding avelumab (an immunotherapy) to another anti-cancer drug (sacituzumab govitecan) can help prevent advanced bladder cancer from growing after initial chemotherapy. About 256 participants with locally advanced or metastatic urothelial carcinom…

This study tests a targeted cancer drug called erdafitinib, alone or combined with an immunotherapy (cetrelimab) and/or chemotherapy, in 125 people with advanced urothelial cancer that has spread. The goal is to find safe doses and see if the treatments shrink tumors. Participant…

This phase 2 trial tests a combination of three drugs—pemetrexed, etrumadenant, and zimberelimab—in 10 people with advanced bladder cancer that has a specific genetic change (MTAP deficiency) and has already been treated with immunotherapy. The goal is to see if the combo is safe…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with bladder cancer that has spread to nearby lymph nodes. About 60 participants will receive either chemo alone or chemo plus durvalumab, followed by maintenance durvalumab fo…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This study tests if the drug enfortumab vedotin can safely and effectively shrink or eliminate high-grade urothelial carcinoma in the upper urinary tract before standard surgery. It includes 24 people who cannot take or choose not to take the chemotherapy drug cisplatin. The main…

This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced or spreading bladder cancer who cannot take standard cisplatin chemo. About 72 adults with recurrent or metastatic urothe…

This early-phase trial is testing a combination of two drugs—erdafitinib and enfortumab vedotin—in 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. Erdafitinib blocks a faulty protein that helps cancer grow, while enfortumab vedotin de…

This study tests a combination of two drugs—tazemetostat and pembrolizumab—in people with advanced bladder cancer that has spread. The goal is to find the best dose and see if the combo works better than pembrolizumab alone. About 30 adults with locally advanced or metastatic uro…

This phase 2 trial tests a drug called sapanisertib in 17 people with advanced bladder cancer that has a specific genetic change (TSC1 or TSC2 mutation). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if the drug can shrink tumors and h…

This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This phase 3 study tests whether a combination of disitamab vedotin and pembrolizumab works better than standard chemotherapy for people with advanced bladder cancer that has spread. The cancer must have a protein called HER2. About 412 participants will be randomly assigned to e…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This study tests a combination of two drugs, pemetrexed and avelumab, in people with a specific type of advanced bladder cancer that lacks a protein called MTAP. The goal is to see if this treatment can shrink or control the cancer. About 18 participants who have already tried ch…

This phase 1/2 trial tests the immunotherapy drug durvalumab alone or combined with other treatments (BCG, radiation, or chemotherapy) in 55 people with non-muscle invasive bladder cancer. The goal is to find safe doses and see if these combinations can eliminate cancer and preve…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy helps people with advanced bladder cancer that has not been treated before. Participants have a type of bladder cancer that has spread or cannot be removed by surgery and shows a protein c…

This phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy helps people with advanced bladder cancer live longer. About 420 adults who have not had prior treatment for their advanced cancer will receive either tislelizumab plus chemo or a placebo…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This phase II trial is testing a combination of two drugs—sEphB4-HSA and pembrolizumab (Keytruda)—in 70 people with advanced bladder or prostate cancers that have not responded to standard treatments. The goal is to see if the combo is safe and can shrink tumors. Participants rec…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people whose prostate, bladder, or kidney cancer has spread. The main goals are to find the safest dose and see what side effects occur. About 65 participants will receive both drugs t…

This study is testing a new combination of two immunotherapy drugs (BGB-A445 and tislelizumab) in about 113 people with advanced bladder, kidney, or skin cancer that has spread. The goal is to see if the combo can shrink tumors and how safe it is. Participants must have already t…

This early-phase study tests a new immune therapy for people with advanced kidney or bladder cancer. Researchers take a person's own natural killer cells, train them in the lab to better recognize cancer, and give them back along with a protein that boosts immune activity. The ma…

This study tests a drug called UGN-102 for people with a low-grade type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder to destroy tumors without surgery. The main goal is to see if the cancer disappears completely after 3 months.…

This early-phase study tests a combination of three drugs (tremelimumab, durvalumab, and belinostat) in people with advanced bladder cancer that has spread or cannot be removed surgically. The main goal is to find the safest dose and understand side effects. About 9 adults who ha…

This study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…

This phase 2 trial is testing whether the immunotherapy drug Keytruda (pembrolizumab) can help people with muscle-invasive bladder cancer avoid having their bladder removed. About 46 participants will receive two cycles of Keytruda, then doctors will check if the cancer has compl…

This study looks at adding the immunotherapy drug atezolizumab to standard chemotherapy (gemcitabine and cisplatin) for people with advanced or metastatic bladder cancer that cannot be removed by surgery. Researchers want to see if giving the drugs in a different order—chemothera…

This study tests two immunotherapy drugs (nivolumab with or without urelumab) given before bladder removal surgery in 15 patients with muscle-invasive bladder cancer who cannot or refuse standard chemotherapy. The goal is to see if adding urelumab boosts the immune response again…

This study tests whether adding an immune-boosting drug called N-803 to the standard BCG treatment works better than BCG alone for people with a high-risk type of bladder cancer that hasn't invaded the muscle. About 369 participants will receive either the combination or BCG alon…

This study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs (like pembrolizumab or nivolumab) after about a year instead of continuing indefinitely. The goal is to see if stopping early leads to similar survival rates while reducing side ef…

This early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…

This was a small early-stage trial testing a mix of three drugs (N-803, pembrolizumab, and enfortumab vedotin) for people with advanced bladder cancer who had not yet received any treatment. The goal was to see if the combination was safe and could slow cancer growth. However, th…

This pilot study is testing whether a less frequent dosing schedule of the drug enfortumab vedotin (EV), given alone or with pembrolizumab, can still control advanced bladder cancer. About 60 adults with locally advanced or metastatic urothelial carcinoma will receive EV on a mod…

This early-phase trial tests whether combining two drugs—avelumab (an immunotherapy) and AVB-S6-500 (a targeted therapy)—is safe and can help people with advanced bladder cancer that has worsened after chemotherapy. Nineteen adults with inoperable or metastatic urothelial carcino…

This early-stage study is testing a combination of three drugs—sacituzumab tirumotecan, enfortumab vedotin, and pembrolizumab—in people with advanced bladder cancer that has spread or cannot be surgically removed. The trial has two parts: first, to find safe doses of the two-drug…

This phase 2 trial is testing whether adding propranolol, a common blood pressure drug, to standard immunotherapy can help control advanced bladder cancer. The study enrolled 6 adults with urothelial carcinoma that has spread or cannot be removed by surgery. Researchers are prima…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This study tests a new drug, UGN-103, given directly into the bladder for people with a low-grade, non-invasive bladder cancer that has a medium risk of coming back. The main goal is to see if the drug can make tumors disappear completely after 3 months. Researchers will also tra…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (gemcitabine and cisplatin) is safe and works better for people with advanced bladder cancer. About 54 participants will receive the combination treatment. The goal is to see if the combo…

This study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…

This study tests a combination of three drugs (ipilimumab, nivolumab, and sacituzumab govitecan) as a first treatment for people with advanced bladder cancer who cannot take standard chemotherapy. About 46 adults will participate to find the best dose and see how well the drugs s…

This early-stage trial tests a new way to treat high-grade bladder cancer that hasn't spread into the muscle. Doctors take immune cells from the patient's own tumor, grow them in a lab, and put them back into the bladder. The goal is to see if this is safe and can shrink or elimi…

This early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…

This study tests a combination of three drugs—ixazomib, gemcitabine, and doxorubicin—in people with advanced bladder cancer that has spread or cannot be removed by surgery. The goal is to find the safest dose and see if the combo can shrink tumors. About 57 adults will take part …

This trial was designed to test two drugs—erdafitinib and atezolizumab—for people with muscle invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. Erdafitinib targets a specific gene change that can drive cancer growth, while atezolizumab helps the im…

This study tests whether adding either favezelimab or vibostolimab to the standard combination of pembrolizumab and enfortumab vedotin works better for advanced bladder cancer that has spread. About 390 people who have not had prior treatment for advanced disease will take part. …

Researchers at Fox Chase Cancer Center are testing whether a standardized cystoscopy exam with tissue sampling, done right before radical cystectomy, can reliably predict which bladder tumors have disappeared (pT0). The study enrolls 65 adults with urothelial carcinoma scheduled …

This study is testing a new, non-invasive urine test called Cxbladder Triage-Plus to see if it can accurately detect bladder cancer in people who have microscopic blood in their urine. Currently, these patients often need a cystoscopy, an invasive procedure where a camera is inse…

Researchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study compares two imaging techniques—CT urography (CTU) and intravenous urography (IVU)—in 133 bladder cancer patients to see if CTU alone can effectively monitor the disease. Researchers want to determine if CTU provides clear enough images of the urinary tract to replace …

This study compares two CT urography methods for diagnosing urothelial carcinoma (a type of urinary tract cancer). 352 adults with blood in urine or a history of this cancer will be randomly assigned to receive either a single-bolus or split-bolus CT scan. Researchers will compar…

This study enrolls 4,000 people with urothelial carcinoma to test whether artificial intelligence can predict HER2 expression using MRI scans and pathology images. The goal is to create a model that accurately assesses HER2 status without needing invasive biopsies, helping doctor…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This study is testing a new urine test called Bladder CARE™ to see if it can detect bladder cancer in people whose standard tests (cystoscopy or cytology) gave unclear results. About 80 adults with suspicious but inconclusive findings will provide a urine sample before their rout…

This study looks at whether a blood test can detect certain genetic changes (FGFR mutations) in patients with advanced bladder cancer better than the standard tissue biopsy. Currently, only patients with these mutations found in tumor tissue can get the drug erdafitinib. The bloo…

This study tests whether whole brain radiation can lower the chance of brain tumors in people with small cell carcinoma of the urinary tract (including the bladder). The 31 participants have already had chemotherapy and responded well. They receive radiation to the brain for 3 we…

This study examines stored tumor samples from 15 people with kidney or bladder cancer who initially responded to immune checkpoint therapy but later developed new tumors. Researchers will compare the genetic and tissue features of the original and new tumors to understand how the…

This small phase II trial is studying whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well patients with advanced bladder cancer respond to the immunotherapy drug nivolumab. Six participants with metastatic urothelial cancer whose tu…